Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
M&A / Property

Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia

By The Northwire Desk — AI Analysis Dec 18, 2025 · 18:33 4565 · None None
4565 · Price

Executive Summary

  • Boehringer Ingelheim elected not to exercise its exclusive option to license Nxera’s GPR52 agonist program for schizophrenia, including lead compound NXE’149.
  • All rights, data, and IP from the collaboration revert to Nxera, leaving the program fully under company control and Phase 2‑ready.
  • Nxera will initiate a formal out‑licensing process in 2026 to seek a new partner for the GPR52 agonist portfolio.

Key Details

  • Collaboration outcome: Boehringer Ingelheim declined the license option; no further information was provided.
  • Reversion of rights: Nxera regains full ownership of the GPR52 portfolio, including all data and intellectual property generated under the original Collaboration and License Option Agreement.
  • Program status: NXE’149 is Phase 2‑ready after a successful Phase 1 trial demonstrating:
  • Favorable safety profile with no severe or serious adverse events and no discontinuations.
  • Dose‑proportional exposure, equivalent free concentrations in plasma and CSF at steady state, and a long half‑life supporting once‑daily dosing.
  • Pharmacodynamic signals indicating engagement of brain circuitry relevant to schizophrenia (cognitive assessments, neurophysiological measures, peripheral biomarkers).
  • Therapeutic potential: The GPR52 agonist program is designed to address positive, negative, and cognitive symptoms of schizophrenia—an advantage over current therapies that target only positive symptoms.
  • Strategic plan: Nxera intends to launch a formal out‑licensing process in 2026, targeting major pharmaceutical or specialist neuroscience companies for partnership.
  • Financial impact: The event has no impact on Nxera’s consolidated financial results for the current accounting period.

Notable Quotes

“Although we are disappointed that Boehringer Ingelheim has chosen not to proceed with the license option, its decision does not diminish the significant potential of the GPR52 agonist program… We are energised by the strong scientific and clinical foundations already established and see meaningful opportunity in regaining full rights.” – Christopher Cargill, CEO & President, Nxera Pharma.

Read the original news release →

More from None

Jun 30, 2026 · 04:27

AI-driven GPCR drug discovery platform monetizing partnerships while transitioning to a profitable specialty pharma model in APAC.

Other Jun 10, 2026 · 02:35

AI-driven GPCR drug discovery platform accelerates pipeline through strategic consortium membership and milestone-driven revenue turnaround.

M&A / Property Jun 01, 2026 · 19:30

Nxera Accelerates Vamorolone Rollout in South Korea as APAC Specialty Pharma Strategy Gains Traction

Regulatory May 11, 2026 · 02:34

GPCR spin-out reels in $275M in biobucks and equity, keeping Asia rights and cash burn in check

M&A / Property May 08, 2026 · 06:26

Nxera Pharma Defends Core IP Amidst Profitability Turnaround

Regulatory May 01, 2026 · 02:36

Nxera Pharma Turns Profitable on Milestone Surge, But Cash Burn Raises Liquidity Questions

Earnings